156406-33-6 Usage
Description
9-keto Fluprostenol is an analog of prostaglandin E2 (PGE2) with structural modifications intended to give it a prolonged half-life and greater potency. Fluprostenol is a well-studied, potent analog of PGF2α and acts primarily through the FP receptor. Oxidation at C-9 of fluprostenol yields 9-keto fluprostenol. It is anticipated that this analog will have strong affinity for EP receptors and act as a PGE2 agonist. However, no studies on the pharmacology of this compound have been published to date.
Uses
Different sources of media describe the Uses of 156406-33-6 differently. You can refer to the following data:
1. 9-keto Fluprostenol is an analog of prostaglandin E2 (PGE2) with structural modifications intended to give it a prolonged half-life and greater potency. Fluprostenol is a well-studied, potent analog of PGF2α and acts primarily through the FP receptor. Oxidation at C-9 of fluprostenol yields 9-keto fluprostenol. It is anticipated that this analog will have strong affinity for EP receptors and act as a PGE2 agonist. However, no studies on the pharmacology of this compound have been published to date.
2. 9-Keto Fluprostenol is an impurity of Fluprostenol (F500753), a FP prostaglandin receptor.
Check Digit Verification of cas no
The CAS Registry Mumber 156406-33-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,4,0 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 156406-33:
(8*1)+(7*5)+(6*6)+(5*4)+(4*0)+(3*6)+(2*3)+(1*3)=126
126 % 10 = 6
So 156406-33-6 is a valid CAS Registry Number.
156406-33-6Relevant articles and documents
9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
-
Page/Page column 17-18, (2010/11/30)
9,11-Cycloendoperoxide derivatives of biologically active prostaglandin analogs, and particularly of the ocular hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H2 1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide prostaglandin analogues that are capable of providing sustained ocular and other in vivo concentrations of the respective drugs. The compounds of the invention have the formula shown below where the variables have the meaning defined in the specification.
